CSL Limited

CHIA:CSL Stock Report

Market Cap: AU$138.1b

CSL Valuation

Is CSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CSL (A$285.81) is trading below our estimate of fair value (A$402.36)

Significantly Below Fair Value: CSL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSL?

Key metric: As CSL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CSL. This is calculated by dividing CSL's market cap by their current earnings.
What is CSL's PE Ratio?
PE Ratio34x
EarningsUS$2.64b
Market CapUS$89.72b

Price to Earnings Ratio vs Peers

How does CSL's PE Ratio compare to its peers?

The above table shows the PE ratio for CSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average58.3x
TLX Telix Pharmaceuticals
161.8x38.3%AU$8.0b
CUV Clinuvel Pharmaceuticals
18.3x26.2%AU$653.8m
REGN Regeneron Pharmaceuticals
17.4x7.6%US$81.0b
AMGN Amgen
35.6x19.4%US$150.5b
CSL CSL
34x13.0%AU$138.1b

Price-To-Earnings vs Peers: CSL is good value based on its Price-To-Earnings Ratio (34x) compared to the peer average (58.3x).

Price to Earnings Ratio vs Industry

How does CSL's PE Ratio compare vs other companies in the Global Biotechs Industry?

19 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CSL 34.0xIndustry Avg. 26.1xNo. of Companies19PE020406080100+
19 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CSL is expensive based on its Price-To-Earnings Ratio (34x) compared to the Global Biotechs industry average (26.1x).

Price to Earnings Ratio vs Fair Ratio

What is CSL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34x
Fair PE Ratio32.2x

Price-To-Earnings vs Fair Ratio: CSL is expensive based on its Price-To-Earnings Ratio (34x) compared to the estimated Fair Price-To-Earnings Ratio (32.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CSL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$285.81
AU$330.65
+15.7%
6.2%AU$357.08AU$285.30n/a15
Nov ’25AU$282.22
AU$328.47
+16.4%
6.3%AU$353.95AU$278.93n/a15
Oct ’25AU$288.47
AU$313.28
+8.6%
6.4%AU$346.82AU$266.76n/a14
Sep ’25AU$307.16
AU$309.80
+0.9%
9.6%AU$343.65AU$223.28n/a15
Aug ’25AU$311.73
AU$322.16
+3.3%
9.6%AU$367.17AU$232.31n/a15
Jul ’25AU$292.29
AU$307.61
+5.2%
8.2%AU$331.43AU$227.07n/a16
Jun ’25AU$283.77
AU$306.71
+8.1%
8.2%AU$334.06AU$228.87n/a16
May ’25AU$274.42
AU$305.66
+11.4%
9.4%AU$339.01AU$232.45n/a16
Apr ’25AU$288.43
AU$303.83
+5.3%
9.0%AU$341.20AU$232.95n/a16
Mar ’25AU$282.09
AU$301.50
+6.9%
9.0%AU$334.83AU$231.44n/a16
Feb ’25AU$297.39
AU$321.83
+8.2%
6.3%AU$352.41AU$278.23n/a15
Jan ’25AU$286.75
AU$308.65
+7.6%
4.3%AU$343.39AU$288.82n/a16
Dec ’24AU$262.62
AU$311.54
+18.6%
4.1%AU$349.56AU$294.01n/a16
Nov ’24AU$234.35
AU$323.64
+38.1%
4.8%AU$361.36AU$300.30AU$282.2216
Oct ’24AU$250.32
AU$328.43
+31.2%
4.0%AU$361.13AU$300.11AU$288.4716
Sep ’24AU$268.67
AU$326.82
+21.6%
5.8%AU$360.64AU$270.09AU$307.1618
Aug ’24AU$269.44
AU$325.65
+20.9%
6.2%AU$352.98AU$261.58AU$311.7318
Jul ’24AU$277.01
AU$326.90
+18.0%
6.2%AU$349.81AU$259.04AU$292.2918
Jun ’24AU$310.05
AU$352.10
+13.6%
6.9%AU$376.39AU$265.34AU$283.7718
May ’24AU$303.15
AU$338.98
+11.8%
7.1%AU$361.57AU$254.89AU$274.4217
Apr ’24AU$288.30
AU$341.11
+18.3%
7.0%AU$365.29AU$257.73AU$288.4317
Mar ’24AU$293.29
AU$340.93
+16.2%
7.1%AU$362.93AU$256.06AU$282.0917
Feb ’24AU$300.81
AU$314.46
+4.5%
7.7%AU$345.52AU$248.58AU$297.3916
Jan ’24AU$287.79
AU$319.60
+11.1%
6.4%AU$347.91AU$265.12AU$286.7516
Dec ’23AU$298.90
AU$309.44
+3.5%
6.2%AU$338.25AU$260.23AU$262.6216
Nov ’23AU$282.42
AU$316.32
+12.0%
4.6%AU$336.58AU$277.21AU$234.3516

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

AVITA Medical

US$338.4m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.91

7D

-0.3%

1Y

18.5%

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.63

7D

1.6%

1Y

-18.5%

Medical Developments International

AU$46.8m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.41

7D

-3.5%

1Y

-45.3%